Atherosclerosis
Volume 196, Issue 2 , Pages 523-531 , February 2008

Secretory products from human adipocytes impair endothelial function via nuclear factor κB

  • Susan Kralisch

      Affiliations

    • University of Leipzig, Department of Internal Medicine III, 04103 Leipzig, Germany
    • ,
  • Grit Sommer

      Affiliations

    • University of Leipzig, Department of Internal Medicine III, 04103 Leipzig, Germany
    • ,
  • Verena Stangl

      Affiliations

    • Med. Klinik Kardiologie, Universitätsmedizin Berlin, Charité Campus Mitte, 10117 Berlin, Germany
    • ,
  • Uwe Köhler

      Affiliations

    • St. Georg Hospital, Department of Obstetrics and Gynecology, 04129 Leipzig, Germany
    • ,
  • Jürgen Kratzsch

      Affiliations

    • University of Leipzig, Institute of Laboratory Medicine, Clinical Chemistry, and Molecular Diagnostics, 04103 Leipzig, Germany
    • ,
  • Holger Stepan

      Affiliations

    • University of Leipzig, Department of Obstetrics and Gynecology, 04103 Leipzig, Germany
    • ,
  • Renaldo Faber

      Affiliations

    • University of Leipzig, Department of Obstetrics and Gynecology, 04103 Leipzig, Germany
    • ,
  • Andreas Schubert

      Affiliations

    • Fraunhofer Institute for Cell Therapy and Immunology, 04103 Leipzig, Germany
    • ,
  • Ulrike Lössner

      Affiliations

    • University of Leipzig, Department of Internal Medicine III, 04103 Leipzig, Germany
    • ,
  • Angelika Vietzke

      Affiliations

    • Med. Klinik Kardiologie, Universitätsmedizin Berlin, Charité Campus Mitte, 10117 Berlin, Germany
    • ,
  • Matthias Bluher

      Affiliations

    • University of Leipzig, Department of Internal Medicine III, 04103 Leipzig, Germany
    • Interdisciplinary Center for Clinical Research (IZKF) Leipzig, 04103 Leipzig, Germany
    • ,
  • Michael Stumvoll

      Affiliations

    • University of Leipzig, Department of Internal Medicine III, 04103 Leipzig, Germany
    • Interdisciplinary Center for Clinical Research (IZKF) Leipzig, 04103 Leipzig, Germany
    • ,
  • Mathias Fasshauer

      Affiliations

    • University of Leipzig, Department of Internal Medicine III, 04103 Leipzig, Germany
    • Interdisciplinary Center for Clinical Research (IZKF) Leipzig, 04103 Leipzig, Germany
    • Corresponding Author InformationCorresponding author at: Ph.-Rosenthal, Street 27, 04103 Leipzig, Germany. Tel.: +49 341 9713318; fax: +49 341 9713389.

Received 25 October 2006 ,Revised 20 April 2007 ,Accepted 17 May 2007.

References 

  1. Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia. 2003;46:1594–1603
  2. Brook RD, Bard RL, Rubenfire M, Ridker PM, Rajagopalan S. Usefulness of visceral obesity (waist/hip ratio) in predicting vascular endothelial function in healthy overweight adults. Am J Cardiol. 2001;88:1264–1269
  3. Williams IL, Chowienczyk PJ, Wheatcroft SB, et al. Effect of fat distribution on endothelial-dependent and endothelial-independent vasodilatation in healthy humans. Diabetes Obes Metab. 2006;8:296–301
  4. Suh HS, Park YW, Kang JH, et al. Vascular endothelial dysfunction tested by blunted response to endothelium-dependent vasodilation by salbutamol and its related factors in uncomplicated pre-menopausal obese women. Int J Obes (Lond). 2005;29:217–222
  5. Watts K, Beye P, Siafarikas A, et al. Exercise training normalizes vascular dysfunction and improves central adiposity in obese adolescents. J Am Coll Cardiol. 2004;43:1823–1827
  6. Vazquez LA, Pazos F, Berrazueta JR, et al. Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. J Clin Endocrinol Metab. 2005;90:316–322
  7. McKay MK, Hester RL. Role of nitric oxide, adenosine, and ATP-sensitive potassium channels in insulin-induced vasodilation. Hypertension. 1996;28:202–208
  8. Fasshauer M, Paschke R, Stumvoll M. Adiponectin, obesity, and cardiovascular disease. Biochimie. 2004;86:779–784
  9. Shimabukuro M, Higa N, Asahi T, et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab. 2003;88:3236–3240
  10. Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 2001;103:1057–1063
  11. Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med. 1999;245:621–625
  12. Aldhahi W, Hamdy O. Adipokines, inflammation, and the endothelium in diabetes. Curr Diab Rep. 2003;3:293–298
  13. Wang P, Ba ZF, Chaudry IH. Administration of tumor necrosis factor-alpha in vivo depresses endothelium-dependent relaxation. Am J Physiol. 1994;266:H2535–H2541
  14. Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation. 1997;96:3042–3047
  15. Schafer K, Halle M, Goeschen C, et al. Leptin promotes vascular remodeling and neointimal growth in mice. Arterioscler Thromb Vasc Biol. 2004;24:112–117
  16. Singhal A, Farooqi IS, Cole TJ, et al. Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease?. Circulation. 2002;106:1919–1924
  17. Kawanami D, Maemura K, Takeda N, et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun. 2004;314:415–419
  18. Verma S, Li SH, Wang CH, et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation. 2003;108:736–740
  19. Savage DB, Sewter CP, Klenk ES, et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes. 2001;50:2199–2202
  20. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 1973;52:2745–2756
  21. Kratzsch J, Berthold A, Lammert A, et al. A rapid, quantitative immunofunctional assay for measuring human leptin. Horm Res. 2002;57:127–132
  22. Grau GE, Lou J. TNF in vascular pathology: the importance of platelet-endothelium interactions. Res Immunol. 1993;144:355–363
  23. Myers PR, Parker JL, Tanner MA, Adams HR. Effects of cytokines tumor necrosis factor alpha and interleukin 1 beta on endotoxin-mediated inhibition of endothelium-derived relaxing factor bioactivity and nitric oxide production in vascular endothelium. Shock. 1994;1:73–78
  24. Hermann C, Assmus B, Urbich C, Zeiher AM, Dimmeler S. Insulin-mediated stimulation of protein kinase Akt: a potent survival signaling cascade for endothelial cells. Arterioscler Thromb Vasc Biol. 2000;20:402–409
  25. Burnett MS, Lee CW, Kinnaird TD, et al. The potential role of resistin in atherogenesis. Atherosclerosis. 2005;182:241–248
  26. Quehenberger P, Exner M, Sunder-Plassmann R, et al. Leptin induces endothelin-1 in endothelial cells in vitro. Circ Res. 2002;90:711–718
  27. Bouloumie A, Marumo T, Lafontan M, Busse R. Leptin induces oxidative stress in human endothelial cells. FASEB J. 1999;13:1231–1238
  28. Park HY, Kwon HM, Lim HJ, et al. Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp Mol Med. 2001;33:95–102
  29. Skilton MR, Nakhla S, Sieveking DP, Caterson ID, Celermajer DS. Pathophysiological levels of the obesity related peptides resistin and ghrelin increase adhesion molecule expression on human vascular endothelial cells. Clin Exp Pharmacol Physiol. 2005;32:839–844
  30. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999;100:2473–2476
  31. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation. 2000;102:1296–1301
  32. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem. 2003;278:45021–45026
  33. Kobayashi H, Ouchi N, Kihara S, et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res. 2004;94:e27–e31
  34. Wilson SH, Best PJ, Edwards WD, et al. Nuclear factor-kappaB immunoreactivity is present in human coronary plaque and enhanced in patients with unstable angina pectoris. Atherosclerosis. 2002;160:147–153
  35. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol. 1994;10:405–455
  36. Chia MC. The role of adhesion molecules in atherosclerosis. Crit Rev Clin Lab Sci. 1998;35:573–602
  37. Wang TD, Chen WJ, Lin JW, Chen MF, Lee YT. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol. 2004;93:362–365
  38. Campia U, Matuskey LA, Panza JA. Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation. 2006;113:867–875
  39. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. Lancet. 2005;366:1279–1289
  40. Lehrke M, Lazar MA. The many faces of PPARgamma. Cell. 2005;123:993–999
  41. Yu JG, Javorschi S, Hevener AL, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes. 2002;51:2968–2974
  42. Motoshima H, Wu X, Sinha MK, et al. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab. 2002;87:5662–5667
  43. Yang WS, Jeng CY, Wu TJ, et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care. 2002;25:376–380
  44. Combs TP, Wagner JA, Berger J, et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology. 2002;143:998–1007
  45. Hallakou S, Doare L, Foufelle F, et al. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes. 1997;46:1393–1399
  46. Zhang B, Graziano MP, Doebber TW, et al. Down-regulation of the expression of the obese gene by an antidiabetic thiazolidinedione in Zucker diabetic fatty rats and db/db mice. J Biol Chem. 1996;271:9455–9459
  47. Kallen CB, Lazar MA. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci USA. 1996;93:5793–5796
  48. de Vos P, Lefebvre AM, Miller SG, et al. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. J Clin Invest. 1996;98:1004–1009
  49. Okuno A, Tamemoto H, Tobe K, et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest. 1998;101:1354–1361

PII: S0021-9150(07)00366-8

doi: 10.1016/j.atherosclerosis.2007.05.016

Atherosclerosis
Volume 196, Issue 2 , Pages 523-531 , February 2008

Article Tools

* Image Usage & Resolution